Læknablaðið - 15.01.2008, Page 55

U M R Æ Ð U R
LYFJAIÐNAÐURINN OG Þ R
0 G FRÉTTIR
ÓUNARLÖND
Þakkir
Birni Guðbjörnssyni og Védísi Skarphéðins-
dóttur eru færðar bestu þakkir fyrir aðstoð
við frágang greinarinnar. Greinin byggir að
stofni til á fyrirlestri sem fluttur var á ársfundi
Vísindasiðanefndar 2007.
Heimildir
1. Benatar SR. Distributive Justice and Clinical Trials in the
Third World. Theor Med 2001; 22:169-76.
2. Bhutta ZA. Ethics in international health research: a
perspective from the developing world. Bull World Health
Organ 2002; 80:114-8.
3. Anderson GF, Chu E. Expanding Priorities - Confronting
Chronic Diseases in Countries with Low Income. N Engl J
Med 2007; 356: 209-11.
4. Caballero B. Ethical issues for collabarative research in
developing countries. Am J Clin Nutr 2002; 76: 717-20.
5. Hyder AA, Wali SA. Informed consent and collaborative
research: perspectives from the developing world. Dev
World Bioeth 2006; 6: 33-40.
6. www.ahrp.org/infomail/1200/20.php
7. Ford J, Tomossy G. Clinical Trials in Developing Countries:
The Plaintiff's Challenge. Law, Social Justice & Global
Development Joumal (LGD) 2004 (1). Nettímarit. _www2.
warwick.ac.uk/fac/soc/law/elj/lgd/2004_l/ford/
8. www.washingtonpost.com/ac2/wp-dyn/A11939-
2000Decl5
9. www.washingtonpost.com/wp-dyn/content/
article/2006/05/06/AR2006050601338.html
10. Killen J, Grady C, Folkers GK, Fauci AS. Ethics of clinical
research in the developing world. Nat Rev Immunol 2002; 2:
210-5.
11. Charatan F. Surfactant trials in Latin America criticised. Brit
Med J 2001; 322:575
12. Lackey DP. Clinical trials in Developing Countries: a review
of the moral issues. Mt Sinai J Med 2001; 68: 4-12.
13. Lo B, Bayer R. Establishing ethical trials for treatment and
prevention of AIDS in developing countries. BMJ 2003; 327:
337-9.
14. GhathiiJT. Third World perspectives on Global Pharmaceutical
access. í: Santoro MA, Gorre TM ritstj. Ethics and the
Pharmaceutical Industry. Cambridge: Cambridge University
Press 2005: 336-51.
15. Kremer M. Pharmaceutical and the Developing World. J Econ
Perspect 2002; 16: 67-90.
16. Kapczynski A. Strict Intemational Patent Laws Hurt
developing Countries. YaleGlobal online 2002. Nettímarit.
yaleglobal.yale.edu/article.print?id=562,
17. Musungu SF, Oh C. The Use of Flexibilities by TRIPS in
Developing Countries:can they promote access to medicines?
Genf: South Centre (WTO) 2005.
18. OXFAM. Patents versus Patients: Five years after the Doha
Declaration. Oxfam briefing paper 95. Oxford: Oxfam 2006.
19. Mandavilli A. Petition aims to maintain cheap dmgs.
Naturenews 2007. Nettímarit. www.nature.com/
news/2007/070115/pf/070115-l_pf.html
20. Mueller JM. Taking TRIPS to India - Novartis, Patent Law
and Access to Medicines. N Engl J Med 2007; 356: 541-3.
21. www.nytimes.com/2007/08/07/business/worldbusiness/
07drug.html?_r=l&ex=1189656000&en=b84b76bb0f750a0c&
ei=5070&oref=slogin
22. Menkes DB. Hazardous Dmgs in Developing Countries. BMJ
1997; 315:1557-8.
23. Bhutta TA. Medicine and books. Deception and design:
Pharmaceutical promotion in the third world. BMJ 1996; 313:
60.
24. Dukes G. The Law and Ethics of the Pharmaceutical Industry.
Amsterdam: Elsevier 2006
25. StahlL.www.cbsnews.com/stories/2004/11 /18/60minutes/
main656458.shtml
26. Bhatt A. "Bio-piracy" - a discussion of some important cases.
The Singapore Law Gazette 2004. www.lawgazette.com.
sg/2004-8/featurel.pdf
27. OXFAM, VSO og Save the Children: Beyond Philanthropy:
the pharmaceutical industry, corporate social responsibility
and the developing world. Oxford: Oxfam 2002.
28. Ringeling, AB: European Experience with Tools of
Govemment. I: Salamon, LM ritst. Tools of Govemment. A
Guide to the New Govemance. Oxford: Oxford University
Press 2002: 585-99.
29. Danska utanríkisráðuneytið. A World of Difference.
The Govemment's Vision for New Priorities in Danish
Development Assistance 2004-2008. www.um.dk/NR/
rdonlyres/44C6C9FF-55FF-4661-AF8F-668172F16C7C/0/
a_world_of_difference.pdf
30. Foege WH. Blurring the lines: Public and Private partnerships
Addressing Global Health. í: Santoro, MA og Gorre, TM
ritstj. Ethics and the Pharmaceutical Industry. Cambridge:
Cambridge University Press 2005: 386-92.
Fræðsludagur heimilislækna
29. febrúar og 1. mars 2008
Hinn árlegi fræðslu- og fagnaðardagur Félags íslenskra heimilislækna verður haldinn á Hilton hótelinu.
Fræðsludagurinn hefst með vinnubúðum að kvöldi 29. febrúar og síðan verður hefðbundin dagskrá laugardaginn
1. mars.
Öldrunarlæknar og endurhæfingarlæknar eru sem fyrr hjartanlega velkomnir.
Dagurinn er skipulagður af FÍH og styrktur af AstraZeneca.
Nánari dagskrá síðar.
Fræðslunefnd FÍH
AstraZeneca
LÆKNAblaðið 2008/94 55